Roman516
6 minutes ago
No Gro, wasting time,
Per your comments,
"Try Dr. Linda Liau. She is who chose PFS as the lead primary endpoint of the SPORE UCLA trial."
So, what regarding the statistical PFS, in the case of NWBO's the OS results shined, and you already knew this.
HoldHigh
11 minutes ago
More insider trades. In a recent transaction, Peter Healy, a director at Trulieve Cannabis (OTC:TCNNF) Corp. (CSE:TRUL), acquired 8,130 subordinate voting shares of the company. The shares were purchased at a price of $6.05 each, amounting to a total investment of $49,186. This purchase incre